Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22. Read more about Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22.
Comprehensive mass spectrometry screening-derived atlas of HDAC inhibitors reveals histone-specific acetylation changes. Read more about Comprehensive mass spectrometry screening-derived atlas of HDAC inhibitors reveals histone-specific acetylation changes.
Discovery of APO-50815, a potent WEE1 kinase inhibitor with exceptional efficacy against patient-derived colorectal cancer organoids. Read more about Discovery of APO-50815, a potent WEE1 kinase inhibitor with exceptional efficacy against patient-derived colorectal cancer organoids.
Identification of novel covalent ligands that disrupt Acetyl-Lysine binding to the SETDB1 tudor domain. Read more about Identification of novel covalent ligands that disrupt Acetyl-Lysine binding to the SETDB1 tudor domain.
DARPins as pan-reactivators of temperature-sensitive p53 cancer mutants. Read more about DARPins as pan-reactivators of temperature-sensitive p53 cancer mutants.
Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader. Read more about Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader.
Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein Degraders. Read more about Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein Degraders.
Drugs that act on both G protein-coupled receptors (GPCRs) and kinases: potentiation of effects, side effects and general aspects of drug pleiotropy. Read more about Drugs that act on both G protein-coupled receptors (GPCRs) and kinases: potentiation of effects, side effects and general aspects of drug pleiotropy.
Comprehensive kinase inhibitor screening reveals potential therapeutic targets in canine melanoma: A Comparative Precision Oncology study. Read more about Comprehensive kinase inhibitor screening reveals potential therapeutic targets in canine melanoma: A Comparative Precision Oncology study.
Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors. Read more about Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors.
